- Show all
- Alicaforsen - review papers
- Alicaforsen - treatment case series papers
- Alicaforsen - Phase 2 Data
- Antisense
- Inflammatory Bowel Disease
- ICAM-1
- Renzapride - Irritable Bowel Syndrome Phase 2 Data
- Renzapride - Irritable Bowel Syndrome Phase 3 Data
- Renzapride in Systemic Scleroderma - Overall Disease Pathology
- Renzapride in Systemic Scleroderma - Gastrointestinal Involvement
- Renzapride in Cystic Fibrosis - Gastrointestinal Involvement
- Renzapride in Cystic Fibrosis - Therapeutic Effect of "Prides"
- Renzapride in Gastroparesis Phase 2 Data
The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis
Renzapride in Gastroparesis Phase 2 Data
Mackie ADR, Ferrington C, Cowan S & Palmer KR. (1991)
Alimentary Pharmacology & Therapeutics; 5(2):1-5
Effects of cisapride in patients with cystic fibrosis and distal intestinal obstruction syndrome
Renzapride in Cystic Fibrosis - Therapeutic Effect of "Prides"
Koletzko, S., Corey, M., Ellis, L., Spino, M., Stringer, D. A., & Durie, P. R. (1990)
The Journal of Pediatrics, 117(5)
Is Gastroparesis Found More Frequently in Patients with Cystic Fibrosis? A Systematic Review
Renzapride in Cystic Fibrosis - Gastrointestinal Involvement
Corral JE, Corey WD, Mascarenhas MR, Barkin JS, Salathe M & Moshiree B (2016)
Scientifica Volume 2016, Article ID 2918139, 11 pages
Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
Renzapride in Systemic Scleroderma - Gastrointestinal Involvement
Khanna, D. et al. (2011)
Journal of Rheumatology, 38(9), pp. 1920–1924. doi: 10.1371/journal.pone.0178059
Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases
Renzapride in Systemic Scleroderma - Overall Disease Pathology
Malandrini, A. et al. (2010)
The Journal of Rheumatology, 27(5), pp. 1203– 1206
Late-Age Onset Scleroderma
Renzapride in Systemic Scleroderma - Overall Disease Pathology
Manno, R. L. et al. (2011)
Journal of Rheumatology, 38(7), pp. 1317– 1325. doi: 10.3899/jrheum.100956
Renzapride in IBS: is efficacy in the eye of the beholder?
Renzapride - Irritable Bowel Syndrome Phase 3 Data
Ford AC (2010)
Alimentary Pharmacology and Therapeutics, 113
Clinical trial: Renzapride treatment of women with irritable bowel syndrome and constipation – A double-blind, randomized, placebo-controlled, study
Renzapride - Irritable Bowel Syndrome Phase 3 Data
Lembo, A. J., Cremonini, F., Meyers, N., & Hickling, R. (2010)
Alimentary Pharmacology and Therapeutics, 31(9), 979–90
Clinical trial: Renzapride therapy for constipation-predominant irritable bowel syndrome– multicenter, randomized, placebo-controlled, double-blind study in primary healthcare setting
Renzapride - Irritable Bowel Syndrome Phase 2 Data
George AM, Meyers NL & Hickling RI. (2008)
Aliment Pharmacol Ther; 27: 830–7
Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome
Renzapride - Irritable Bowel Syndrome Phase 2 Data
Tack, J., Middleton, S. J., Horne, M. C., Piessevaux, H., Bloor, J. S., Meyers, N. L., & Palmer, R. M. J. (2006)
Alimentary Pharmacology and Therapeutics, 23(11), 1655–1665
Disclaimer
The information in “published papers” is provided by Atlantic Healthcare plc, and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.